Hydroxycarbamid Hikma (Hydroxycarbamide)

Hydroxycarbamide blocks ribonucleotide reductase, an enzyme needed to produce deoxyribonucleotides for DNA synthesis. By depleting these building blocks, the drug halts DNA replication, causing cell‑cycle arrest in rapidly dividing cells such as malignant leukocytes or abnormal erythroid precursors.

The specific dose of Hydroxycarbamid Hikma is determined by the prescribing clinician based on the patient’s diagnosis, disease severity, renal function and blood‑count response. Dosing regimens are individualized and should follow the prescriber’s instructions.

Hydroxycarbamide is classified as Pregnancy Category D, indicating evidence of fetal risk. It should be avoided in pregnancy unless the potential benefit justifies the risk. Breastfeeding is not recommended because the drug is excreted in milk and may affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Hydroxycarbamide is an oral antimetabolite that offers a convenient route of administration compared with injectable agents such as interferon‑alpha or targeted kinase inhibitors. While it is effective for many hematologic disorders, newer targeted therapies may provide higher specificity but often at greater cost and with different safety profiles.

Hydroxycarbamid Hikma should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, excessive heat and direct sunlight to maintain stability.

The medication is taken orally, usually with water. The exact timing (e.g., with food or on an empty stomach) and frequency are determined by the prescribing physician based on the therapeutic goal and patient tolerance.

Serious risks include severe bone‑marrow suppression leading to neutropenia, thrombocytopenia or aplastic anemia, as well as rare skin ulceration and hypersensitivity reactions. Patients should be monitored closely for signs of infection, bleeding or severe skin changes.

Hydroxycarbamide is contraindicated in patients with known hypersensitivity to the drug, in pregnant women unless absolutely necessary, and in individuals with severe renal impairment without dose adjustment. Caution is also advised for patients with existing severe bone‑marrow suppression.